Renalytix to Present at Stifel Healthcare Conference
Renalytix plc (NASDAQ: RNLX) will participate in the Stifel Healthcare Conference on November 15-16, 2022, at the Lotte New York Palace Hotel.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Renalytix plc (NASDAQ: RNLX) will participate in the Stifel Healthcare Conference on November 15-16, 2022, at the Lotte New York Palace Hotel. Attendees can access a live and archived webcast of the presentation on the Company’s website starting at 3:35 p.m. ET on November 16. Renalytix is a pioneer in bioprognosis for kidney health, with its leading product, KidneyIntelX™, holding Breakthrough Designation from the FDA. This innovative solution aims to transform kidney disease prognosis and management.
Details
News Market Reaction – RNLX
The recorded move for RNLX in the trading session of this news was -4.73%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK and SALT LAKE CITY, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will participate in the Stifel Healthcare Conference to be held November 15-16, 2022 at the Lotte New York Palace Hotel. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the Company’s website at https://investors.renalytix.com or via the webcast registration link below beginning at 3:35 p.m. Eastern Time on November 16, 2022.
Webcast registration link: https://wsw.com/webcast/stifel74/rnlx/2129288
About Renalytix
Renalytix (LSE: RENX) (NASDAQ: RNLX) is the global founder and leader in the new field of bioprognosis™ for kidney health. The company has engineered a new solution that enables early-stage chronic kidney disease progression risk assessment. The Company’s lead product, KidneyIntelX™, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.
For further information, please contact:
| Renalytix plc | www.renalytix.com | ||
| James McCullough, CEO | Via Walbrook PR | ||
| Stifel (Nominated Adviser, Joint Broker) | Tel: 020 7710 7600 | ||
| Alex Price / Nicholas Moore | |||
| Investec Bank plc (Joint Broker) | Tel: 020 7597 4000 | ||
| Gary Clarence / Daniel Adams | |||
| Walbrook PR Limited | Tel: 020 7933 8780 or renalytix@walbrookpr.com | ||
| Paul McManus / Lianne Applegarth / Alice Woodings | Mob: 07980 541 893 / 07584 391 303 / 07407 804 654 | ||
| CapComm Partners | Tel: 415-389-6400 or investors@renalytix.com | ||
| Peter DeNardo | |||
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.